Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.36 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.36 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.36 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.36 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.36 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TOP1 | P11387 | 1/20 | 0.32 |
| ▸ | SLC11A2 | P49281 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.32 |
| ▸ | FBP1 | P09467 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4090064 | 0.88 | PIK3CD (0.34) | PIK3CDPIK3CAPIK3CGMEN1KMT2A | |
| SCHEMBL4073483 | 0.87 | PIK3CD (0.46) | PIK3CDPIK3CAPIK3CGPSEN1PSEN2 | |
| SCHEMBL3170904 | 0.69 | KMT2A (0.52) | MEN1KMT2AMAPT | |
| SCHEMBL4484753 | 0.65 | MAPT (0.40) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4075677 | 0.64 | MAPT (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4077257 | 0.64 | PIK3CD (0.39) | PIK3CDPIK3CAPIK3CGMEN1KMT2A | |
| SCHEMBL27826404 | 0.64 | CNR1 (0.35) | PIK3CDPIK3CAPIK3CGMEN1KMT2A | |
| SCHEMBL3971702 | 0.62 | PIK3CD (0.38) | PIK3CDPIK3CAPIK3CGMEN1KMT2A | |
| SCHEMBL4080191 | 0.61 | ALOX5 (0.35) | MEN1KMT2AMAPTPRF1 | |
| SCHEMBL4086084 | 0.61 | PIK3CD (0.38) | PIK3CDPIK3CAPIK3CGMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618989-B2 | Tricyclic oxazolidone derivatives useful as PR modulators | WYETH (US) | 2009-11-17 | — | — | US | claimed |
| US-20080045578-A1 | Tricyclic oxazolidone derivatives useful as PR modulators | WYETH (US) | 2008-02-21 | — | — | US | claimed |
| WO-2008021338-A2 | TRICYCLIC OXAZOLIDONE DERIVATIVES USEFUL AS PR MODULATORS | WYETH (US) | 2008-02-21 | — | — | WO | claimed |
| US-7618990-B2 | 4-[2-(4,4-Dimethyl-2-thioxo-1,3-oxazolidin-3-yl)-1,3-thiazol-4-yl]benzonitrile; progesterone receptor (PR); contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, hormone replacement therapy | WYETH (US) | 2009-11-17 | — | — | US | disclosed |
| US-7618989-B2 | Tricyclic oxazolidone derivatives useful as PR modulators | WYETH (US) | 2009-11-17 | — | — | US | disclosed |
| EP-2054410-A2 | OXAZOLIDONE DERIVATIVES AS PR MODULATORS | Wyeth (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20080045556-A1 | Oxazolidone derivatives as PR modulators | WYETH (US) | 2008-02-21 | — | — | US | disclosed |
| US-20080045578-A1 | Tricyclic oxazolidone derivatives useful as PR modulators | WYETH (US) | 2008-02-21 | — | — | US | disclosed |
| WO-2008021338-A2 | TRICYCLIC OXAZOLIDONE DERIVATIVES USEFUL AS PR MODULATORS | WYETH (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021331-A2 | OXAZOLIDONE DERIVATIVES AS PR MODULATORS | WYETH (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045578-A1 | Tricyclic oxazolidone derivatives useful as PR modulators | MC2R, GNRHR, MC3R | PIK3CD 4516/4885PIK3CA 4113/4885PIK3CG 4539/4885 |
| US-20080045556-A1 | Oxazolidone derivatives as PR modulators | MC2R, NPY1R, PRLHR | PIK3CD 4187/4885PIK3CA 3496/4885PIK3CG 4308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.